Telix at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting in Toronto
Melbourne (Australia) | 06 June 2024
Telix today announces eight abstract presentations featuring the Company’s development programs, medical technology (devices) and research and innovation (R&I) at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting being held in Toronto, Canada from June 8 – 11.
Telix’s extensive theranostic pipeline will be showcased in presentations covering TLX591 (177Lu rosopatamab tetraxetan), the Company’s lead investigational radio antibody-drug conjugate (rADC) therapy for prostate cancer; TLX66 (90Y-besilesomab), its investigational bone marrow conditioning therapy; Illuccix® (68Ga-PSMA-11), its approved PSMA-PET[1] imaging agent for prostate cancer; and TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®[2]), its investigational PET imaging agent for kidney cancer. Updates will also be provided on Telix R&I and MedTech, including Lightpoint’s SENSEI® robotic-assisted gamma probe.
Telix will also host two satellite symposia, the first in collaboration with our partner the University of California, San Francisco (UCSF) on FET-PET[3] imaging of glioma, and the second on next generation imaging for renal cell carcinoma, with leading key opinion leaders. Industry experts will also be on hand at the Telix booth for reader training and advice on interpretation of PSMA-PET/CT.
Visit booth #1225 to meet with the Telix team.
SNMMI presentation details are as follows (all times ET):
Title: Radiation Protection Considerations with TLX250-CDx (89Zr-girentuximab) PET/CT
Presenter: Adnan Chowdhury, MD, Royal Free London NHS Foundation Trust
Date and Time: Saturday, June 8 | 2:00 pm – 3:15 pm
Session: MTA01 POPs/Meet the Author: Educational Exhibits
Format: Poster
Location: Exhibit Hall D – Science Pavilion (Convention Center)
Title: Standardized Template for Clinical Reporting PSMA PET/CT Scans
Presenter: Shadi Esfahani, MD, Massachusetts General Hospital
Date and Time: Saturday, June 8 | 2:00 pm – 3:15 pm
Session: MTA01 POPs/Meet the Author: Educational Exhibits
Format: Poster
Location: Exhibit Hall D – Science Pavilion (Convention Center)
Title: Evaluation of Tumour-Targeting Fusion Proteins that Antagonize TGF-β in the Tumour Microenvironment via Simultaneous Binding to CAIX or PSMA and TGF-β
Presenter: Kwame Twumasi-Boateng, Telix
Date and Time: Saturday, June 8 | 3:30 pm – 4:45 pm
Session: MTA02: POPs/Meet the Author: Oncology, Basic and Translational 1
Format: Poster
Location: Exhibit Hall D – Science Pavilion (Convention Center)
Title: Uncertainty Analysis of Single Time Point Dosimetry in TLX66 (90Y-anti-CD66) Radioimmunotherapy
Presenter: Amit Nautiyal, University Hospital Southampton
Date and Time: Sunday, June 9 | 6:30 pm – 8:30 pm
Session: MTA06 RPSC/CMIIT Science Pavilion Mixer & MTA06 – POPs/Meet the Author Session: Molecular Targeting Probes 1
Format: Poster
Location: Exhibit Hall D – Science Pavilion (Convention Center)
Title: 99mTc-PSMA-I&S Radioguided Salvage Lymphadenectomy for Prostate Cancer: Preliminary Clinical Results from a Prospective Trial
Presenter: Zachary Ells, University of California, Los Angeles
Date and Time: Sunday, June 9 | 6:30 pm – 8:30 pm
Session: MTA06 RPSC/CMIIT Science Pavilion Mixer & MTA06 – POPs/Meet the Author Session: Molecular Targeting Probes 1
Format: Poster
Location: Exhibit Hall D – Science Pavilion (Convention Center)
Title: ProstACT SELECT: Safety, Tolerability, and Dosimetry of TLX591 with Best Standard of Care in Patients with PSMA-expressing Metastatic Castration Resistant Prostate Cancer (Preliminary Results)
Presenter: Nat Lenzo, MD, Nuclear Oncologist and General Internal Medicine Physician
Date and Time: Monday, June 10 | 10:24 am – 10:32 am
Session: IS06 Prostate Cancer – Novel Agents
Format: Oral presentation
Location: 801A (Convention Center)
Title: Trial in Progress: Phase 1B Study of Personalized Ultra-hypofractionated Stereotactic Ablative Radiotherapy of High-Risk Prostate Cancer Guided by PSMA-PET (68Ga PMSA-11) response (PULSAR ProPhet)
Presenter: Orhan K. Oz, MD, PhD, University of Texas Southwestern
Date and Time: Monday, June 10 | 10:00 am – 11:15 am
Session: MTA07 POPs/Meet the Author: Oncology, Basic and Translational 2
Format: Poster
Location: Exhibit Hall D – Science Pavilion (Convention Center)
Title: Comparison of TLX250-CDx (89Zr-girentuximab) PET/CT and PET/MRI Hybrid Systems in Patients with Suspicion of Clear Cell Renal Cell Carcinoma (ccRCC): Initial Results
Presenter: Shams Arifeen, Telix
Date and Time: Tuesday, June 11 | 09:30 am – 10:45 am
Session: MTA10 POPs/Meet the Author: Oncology: Clinical Therapy & Diagnosis 2
Format: Poster
Location: Exhibit Hall D – Science Pavilion (Convention Center)
Reader training: Interpretive PSMA-PET/CT
Presenters:
- Jaideep Sohi, MD, President and Founder, American Molecular Imaging
- Umesh Oza, MD, American Molecular Imaging, American Radiology Associates
Date and Time:
- Sunday, June 9 | 11:00 am – 12:00 pm, 2:30 pm – 3:30 pm
- Monday, June 10 | 11:00 am – 12:00 pm, 3:30 pm – 4:30 pm
Location: Telix Booth #1225
Register here
Satellite Symposium: An academic-industry partnership – UCSF’s FET-PET experience
Presenters:
- Thomas Hope, MD, Vice Chair Department of Radiology and Director of Molecular Therapy, UCSF
- Javier Villaneuva-Meyer, MD, Vice Chair Department of Radiology, UCSF
- John de Groot, MD, Division Chief of Neuro-Oncology, UCSF
- Derek Johnson, MD, Chair of the Division of Nuclear Medicine at Mayo Clinic Rochester
Date and Time: Monday, June 10 | 6:45 am – 7:45 am
Location: Room 701B (Convention Center)
Register here
Satellite Symposium (Hosted Dinner): Next Frontier in Molecular Imaging in RCC
Presenters:
- Jeremie Calais, MD, PhD (UCLA)
- David Schuster, MD, FACR (Emory University School of Medicine)
Date and Time: Monday, June 10 | 5:45 pm – 6:45 pm
Location: Room 701A (Convention Center)
Register here
Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[4], by the Australian Therapeutic Goods Administration (TGA) [5], and by Health Canada[6]. No other Telix product has received a marketing authorisation in any jurisdiction.
[1] Imaging of prostate-specific membrane antigen with positron emission tomography.
[2] Brand name subject to final regulatory approval.
[3] Imaging of 18F-floretyrosine with positron emission tomography.
[4] Telix ASX disclosure 20 December 2021.
[5] Telix ASX disclosure 2 November 2021.
[6] Telix ASX disclosure 14 October 2022.